Then Wnt/β-catenin signaling is prone to be activated when nucleus β-catenin integrating with TCF/LEF transcription factors.4,5 Subsequently, through activation of the TCF encoding genes, Wnt pathway activators would result in the progression and metastasis of CRC.6 Therefore agents exerting inhibitory activities towards Wnt/β-catenin pathways are potentially anti-CRC medicines. The gene discussed is HNF4A; the disease is colorectal carcinoma.